+

WO1992006958A1 - Derives de 4-acetoxy-piperidine, procede servant a leur preparation, et leur utilisation comme antagonistes de recepteur m3 de muscarine - Google Patents

Derives de 4-acetoxy-piperidine, procede servant a leur preparation, et leur utilisation comme antagonistes de recepteur m3 de muscarine Download PDF

Info

Publication number
WO1992006958A1
WO1992006958A1 PCT/GB1991/001810 GB9101810W WO9206958A1 WO 1992006958 A1 WO1992006958 A1 WO 1992006958A1 GB 9101810 W GB9101810 W GB 9101810W WO 9206958 A1 WO9206958 A1 WO 9206958A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
group
quaternary ammonium
ammonium salt
Prior art date
Application number
PCT/GB1991/001810
Other languages
English (en)
Inventor
Richard Bawden Barlow
Mark Anthony Veale
Original Assignee
British Technology Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Technology Group Ltd filed Critical British Technology Group Ltd
Publication of WO1992006958A1 publication Critical patent/WO1992006958A1/fr
Priority to FI922903A priority Critical patent/FI922903A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • This invention relates to esters of N-substituted piperidin-4-ols and to their use as therapeutic agents.
  • a finding in a compound of such selectivity is of greater value than a finding of enhanced, but non-selective, anti-muscarinic receptor activity for a new compound.
  • the comprehensive literature on antimuscarinic N-substituted piperidin-4-ol esters includes the studies reported by Sugai et aj. (Che . Phar . Bull., 1984, 32(3) . 967 and 977, and Japanese Patent Application Number 27570/1979) on tertiary bases and quaternary ammonium salts which contain a substituted or unsubstituted 1 ,3-dioxolan-4-ylmethyl group substituted on the nitrogen atom of the piperidine ring. Accordingly the present invention compri ses a compound of formula ( I)
  • R and R2 are each separately selected from a phenyl group which is unsubstituted or substituted by one or more groups selected from alkyl, alkoxy, alkylenedioxy, halogeno, halogeno substituted alkyl, hydroxy and nitro
  • R3 and R4 are each hydrogen or together are an oxo group
  • R5 is an aromatic group, the compound optionally being in the form of a physiologically acceptable acid addition or quaternary ammonium salt, for use in therapy.
  • R] and R2 are each separately selected from a phenyl group which is unsubstituted or substituted by one or more groups selected from alkyl, alkoxy, alkylenedioxy, halogeno, halogeno substituted alkyl, hydroxy and nitro
  • R3 and R4 are each hydrogen or together are an oxo group and R5 is an aromatic group, the compound optionally being in the form of a physiologically acceptable acid addition or quaternary ammonium salt thereof, but excluding the compound in which R-
  • or R2 are C ⁇ — alkyl groups, for example methyl, ethyl, propyl and isopropyl, C _ alkoxy groups, for example methoxy and ethoxy, C-j_3 alkylenedioxy groups, for example methylenedioxy, fluoro, chloro, bro o and iodo groups, C- j — alkyl groups substituted by one or more halogeno groups, for example three fluoro groups as in trifluoromethyl , hydroxy and nitro.
  • substituents may be present, for example 1 , 2 or 3 monovalent substituents, preferably such substituted phenyl groups contain no more than one substituent (including one alkylenedioxy group) and conveniently the groups R ] and R are identical, especially with each being an unsubstituted phenyl group.
  • the aromatic group R5 may be carbocyclic or heterocyclic and unsubstituted or substituted, suitable heterocyclic groups consisting of a 5- or 6-membered ring system which contains one or two hetero atoms selected from the group consisting of oxygen, nitrogen and sulphur. Although suitable carbocyclic groups R5 are both phenyl and naphthyl, it is generally preferred that R5 is monocyclic.
  • R5 is a non-basic aromatic group so that among the heterocyclic groups thienyl is of greater interest than basic groups such as pyridyl, pyrimidyl, oxazolyl and thiazolyl, although such groups can be used as evidenced by the data presented herein on the compound containing a 2-pyridyl group R5.
  • Preferred groups R5 are thus 2- or 3-thienyl (thienyl indicates the univalent radical " i ⁇ " Jjderived from thiophene) and especially phenyl.
  • Such aromatic groups R5 may be substituted by one or more substituents but preferably no more than one substituent, especially in the case of naphthyl and particularly of phenyl groups.
  • Suitable substituents are broadly as described above for the substituted phenyl groups R- and R , for example methyl, methoxy, fluoro and nitro.
  • R5 halogeno and especially fluoro substituents are of the greatest interest.
  • Substitution may be present at various positions in the ring but in the case of substituted phenyl groups there is particular interest in substitution at the ortho and especially the para positions, substitution at the meta position being less preferred, especially in the case of a nitro group.
  • Unsubstituted groups R5 are, however, generally preferred.
  • tertiary bases (I) can be used in the form of physiologically acceptable salts which may be formed with various suitable inorganic and organic acids.
  • inorganic acids examples include phosphonic acid, nitric acid, sulphuric acid and particularly the hydrohalic acids hydrochloric acid, hydrobromic acid and hydroiodic acid.
  • organic acids examples include citric acid, oxalic acid, fumaric acid, maleic acid, lactic acid, succinic acid, malic acid, tartaric acid and methane sulphonic acid.
  • Formation of such an acid addition salt provides a particularly suitable method of formulating the basic compounds (I).
  • the quaternary salts may contain a variety of groups RX but particularly preferred are those which contain a group R which is an alkyl group substituted by a phenyl group which may optionally itself be substituted, for example as described in relation to the groups R-
  • alkyl groups R may conveniently be as described hereinbefore in relation to alkyl substituents on substituted phenyl groups R- and Rg, for example being isopropyl, propyl, ethyl or particularly methyl.
  • the group X may be of a variety of types, for example corresponding to the anions present in the acid addition salts described hereinbefore. Preferred groups X are however the halogeno groups, for example bromo or chloro.
  • and R2 are as defined for the compound of formula (1) or are groups convertible thereto, with a compound of formula (III).
  • R3 and R4 are as defined for the compound of formula (I) and R5 is as defined for the compound of formula (I) or is a group convertible thereto
  • Y is a suitable leaving group, in particular a halogeno group, for example a chloro or especially a bromo group.
  • the reaction is conveniently effected in solution in a suitable organic solvent such as chloroform using an appropriate temperature and time, for example at room temperature over a period of up to 24 hours.
  • R- and R2 are as defined for the compound of formula (I) or are groups convertible thereto, and Y is a suitable leaving group, with a compound of formula (V)
  • R3 and R4 are as defined for the compound of formula (I) and R5 is as defined for the compound of formula (I) or is a group convertible thereto.
  • Y is in particular a halogeno group, for example a bromo or especially a chloro group, or alternatively an alkoxy group, for example one containing an alkyl group as described hereinbefore in relation to alkyl substituents on substituted phenyl groups R-
  • the reaction is conveniently effected in solution in a suitable organic solvent such as toluene using an appropriate temperature and time, for example at 80°C over a period of up to 24 hours.
  • the free bases (I) often do not form crystalline solids and it is therefore usually convenient to isolate the compound (I) in the form of an acid addition salt by reaction with an acid, for example a monobasic acid. It is also usually preferable to .formulate the compound (I) as a salt, for example with one of the acids described hereinbefore, for example HBr or HC1, and in such an instance the compound may suitably be isolated directly in the form of the acid addition salt which is to be used therapeutically.
  • the compounds (I) may be formulated as a quaternary ammonium salt containing a cation (la) as indicated hereinbefore, although such salts do have disadvantages in terms of oral absorption and ability to cross the blood brain barrier.
  • Such salts may conveniently be formed in several ways. Firstly the compound (1) may be reacted with a compound RX in which R is the additional group present on the nitrogen atom in the quaternary ammonium salt and X ⁇ is the anion present therein. Alternatively a compound of formula (Ha)
  • R3, R4 and R5 are as defined above for formula (III) and X provides the anion present in the quaternary ammonium salt.
  • the quaternary ammonium salts contain an anion which is not a halogeno anion
  • an alkali metal salt for example a sodium or potassium salt
  • R- , R2 and R5 in the compounds of formulae (II), (IV), (V), (III), (Ila) and (Ilia) are identical with those groups in the compound of formula (I) but in some instances it may be convenient for this not to be the case, particularly where these groups are substituted groups and the compounds (II) to (V), (Ila) and (Ilia) contain a substituent or substituents convertible to those present in (I) .
  • the invention encompasses compounds (I) in the various stereochemical forms in which they exist, certain of which may be of particular value by virtue of their level of therapeutic activity and/or physical properties such as greater aqueous solubility, etc.
  • R- and R2 when R- and R2 are different the compounds will contain at least one asymmetric carbon atom and will be resolvable into optically active iso ers.
  • the quaternary ammonium salts can exist in different stereoisomeric forms depending on the relative orientation of the groups -C(R3)(R4)-Rs and R to the rest of the molecule. Such stereochemistry is described in detail by Sugai et al_, ibid, particularly in the Japanese patent application.
  • the antagonist activity of the compounds of the present invention against the uscarinic receptors, particularly against the M3 receptor, renders them of value as spasmolytics (or antispasmodics) which may be used in the treatment of patients with various conditions in which smooth muscle is in spasm.
  • Such conditions include gastrointestinal motility disorders such as the spastic condition of the gut, functional diarrhoea, irritable bowel syndrome, cardiospas , pylorospasm, gastro-oesophaegeal reflux, gastric and duodenal ulcers and also spasm of the bilary and particularly urinary tracts and urinary incontinence.
  • the compounds are of interest in the control of bronchospasm as M3 receptors are involved in cholinergic-induced bronchoconstriction.
  • the particular value of the compounds is their ability to block effects on M3 receptors in concentrations which do not have substantial effects on the beating of the heart.
  • the compounds are of further interest for their anti-secretory activity and in addition to their effects on gastric and intestinal secretion therefore have potential for use in reducing nasal secretion in colds, in reducing sweating and for reducing excessive excretions in conjunction with operative procedures.
  • cardiac-sparing substitutes for atropine as pre-operative medication, particularly in the elderly, and in preparations for suppressing nasal secretions and for reducing sweating.
  • antimuscarinics have been shown to be of value by virtue of a centrally acting effect in the treatment of defects of the central nervous system where the cholinergic or muscarinic mechanisms are malfunctioning, for example Parkinson's and Alzheimer's diseases and other conditions involving cognitive deficiencies.
  • the compounds of the present invention thus have further potential in this area.
  • the compounds (I) may be formulated with a physiologically acceptable diluent or carrier for use as pharmaceuticals for veterinary, for example in an avian or especially a mammalian context, and particularly for human use by a variety of methods.
  • a physiologically acceptable diluent or carrier for use as pharmaceuticals for veterinary, for example in an avian or especially a mammalian context, and particularly for human use by a variety of methods.
  • they may be applied as a composition incorporating a liquid diluent or carrier, for example an aqueous or oily solution, suspension or emulsion, which may often be employed in injectable form for parenteral administration and therefore may conveniently be sterile and pyrogen free.
  • Oral administration may also be used, particularly in the case of the free bases and their acid addition salts, and indeed is preferred.
  • compositions for this purpose may incorporate a liquid diluent or carrier
  • a solid for example a conventional solid carrier material such as starch, lactose, dextrin or magnesium stearate.
  • Such solid compositions may conveniently be of a formed type, for example as tablets, capsules (including spansules), etc.
  • Other forms of administration than by injection or through the oral route may also be considered in both human and veterinary contexts, for example the use of suppositories or pessaries.
  • Another form of pharmaceutical composition is one for baccal or nasal administration, for example lozenges, nose drops or an aerosol spray, or alternatively drops for administration into the eye which may conveniently contain a sterile liquid diluent or carrier.
  • the invention further includes a pharmaceutical composition
  • a pharmaceutical composition comprising a compound (I) as defined hereinbefore together with a physiologically acceptable diluent or carrier.
  • compositions may be formulated in unit dosage form, i.e. in the form of discrete portions each comprising a unit dose, or a multiple or sub-multiple of a unit dose.
  • dosage of active compound given will depend on various factors, including the particular compound which is employed in the composition and the condition treated, it may be stated by way of guidance that a satisfactory spasmolytic effect will often be achieved using a daily dosage of about 0.05 to 40 mg/kg, particularly of about 0.1 to 10 or 20 mg/kg, for example about 1 or 1.5 mg/kg. However, it will be appreciated that it may be appropriate under certain circumstances to give daily dosages either below or above these levels.
  • more than one compound (I) may be administered in the pharmaceutical composition or, indeed, other active compounds may be included in the composition.
  • the present invention therefore includes a compound of formula (I) as defined hereinbefore for use in therapy and also a method for the treatment of a patient in need of anti-spasmodic treatment which comprises administering to said patient a therapeutically effective amount of a compound of formula (I) as defined hereinbefore.
  • the invention is illustrated by the following Examples.
  • Example 2 Comparison of activity of compounds (I) against guinea-pig isolated atria and ileum The procedures used were essentially those described by Barlow and Shepherd, Br. J. Pharmac, 1986, 89., 837-843 as indicated below. (a) Guinea-pig isolated ileum
  • the guinea-pig ileum responses were recorded isotonically with a load of about 0.5 g.
  • the agonist, carbachol was allowed to act for 30 seconds and added once every 90 seconds by relays controlled from a PET microcomputer.
  • the tissue was suspended in Krebs solution aerated with a mixture of 95% O2 and 5% CO2, usually containing 5 yM norphenylephrine and experiments were carried out at 29.8 ⁇ 0.3°C.
  • the atria were set up in Krebs solution aerated with a mixture of 95% O2 and 5% CO2, usually containing 5 yM norphenylephrine (the same solution as was used for the ileum).
  • the temperature was 29.8 ⁇ 0.3°C and the spontaneous contractions were recorded isometrically with a load of about 0.2 g, action potentials also being recorded.
  • the agonist, carbachol was added by relays operated from a Commodore 128 microcomputer and allowed to act for 5 minutes. Doses were given once every 15 minutes with a second wash 10 minutes from the start of the cycle. The effects of the agonist were expressed as the percentage inhibition of the force of the contraction. As in the experiments on the ileum, the control responses were usually obtained with 0.1 and 0.2 ⁇ M carbachol. The tissue was then exposed to the antagonist and the experiment continued as with the ileum. The data obtained for the fourteen compounds (I) of Example 1 is given in Table 2. The dose-ratios obtained are used to calculate the affinity constants which are shown in log form.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

On décrit des composés de formule (I), dans lesquels R1 et R2 sont chacun séparément choisis à partir d'un alkyle, alcoxy, alkylènedioxy, halogéno, alkyle substitué par halogéno, hydroxy et nitro, R3 et R4 représentent chacun hydrogène ou représentent tous deux un groupe oxo et R5 représente un groupe aromatique, le composé se présentant éventuellement sous forme d'une addition d'acide physiologiquement acceptable ou d'un sel d'ammonium quaternaire. Ces composés sont utiles comme antagonistes sélectifs du récepteur M3 de muscarine.
PCT/GB1991/001810 1990-10-23 1991-10-17 Derives de 4-acetoxy-piperidine, procede servant a leur preparation, et leur utilisation comme antagonistes de recepteur m3 de muscarine WO1992006958A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI922903A FI922903A0 (fi) 1990-10-23 1992-06-22 4-acetoxipiperidin derivat, deras framstaellningsfoerfarande och anvaendning som antagonist foer muskarina m-3 receptorer.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909023023A GB9023023D0 (en) 1990-10-23 1990-10-23 Pharmaceutical compositions
GB9023023.6 1990-10-23

Publications (1)

Publication Number Publication Date
WO1992006958A1 true WO1992006958A1 (fr) 1992-04-30

Family

ID=10684199

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1991/001810 WO1992006958A1 (fr) 1990-10-23 1991-10-17 Derives de 4-acetoxy-piperidine, procede servant a leur preparation, et leur utilisation comme antagonistes de recepteur m3 de muscarine

Country Status (9)

Country Link
EP (1) EP0506903A1 (fr)
JP (1) JPH05504578A (fr)
AU (1) AU8714991A (fr)
CA (1) CA2072598A1 (fr)
FI (1) FI922903A0 (fr)
GB (2) GB9023023D0 (fr)
PT (1) PT99299A (fr)
WO (1) WO1992006958A1 (fr)
ZA (1) ZA918381B (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006635A1 (fr) * 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Derive de carbamate et medicament le contenant
EP0801067A1 (fr) * 1994-12-28 1997-10-15 Yamanouchi Pharmaceutical Co. Ltd. Nouveaux derives de quinuclidine et composition pharmaceutique les contenant
US6174900B1 (en) * 1995-06-26 2001-01-16 Ss Pharmaceutical Co., Ltd. Substituted piperidine derivative for treating urinary disturbance
WO2005000815A2 (fr) * 2003-06-24 2005-01-06 Novartis Ag Composes organiques
US8153669B2 (en) 2004-12-24 2012-04-10 Novartis Ag Quaternary ammonium salts as M3 antagonists
US20190023656A1 (en) * 2014-12-19 2019-01-24 The Broad Institute, Inc. Dopamine d2 receptor ligands
US11498896B2 (en) 2014-12-19 2022-11-15 The Broad Institute, Inc. Dopamine D2 receptor ligands

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE92198A1 (es) * 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0309424A2 (fr) * 1987-09-21 1989-03-29 ISTITUTO DE ANGELI S.p.A. Dérivés amidinyls

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE792043A (fr) * 1971-11-30 1973-05-29 Ciba Geigy Derives de la piperidine utilisables pour stabiliser des matieres organiques

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0309424A2 (fr) * 1987-09-21 1989-03-29 ISTITUTO DE ANGELI S.p.A. Dérivés amidinyls

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Chemical and Pharmaceutical Bulletin, vol. 32, no. 3, 3 March 1984, Tokyo (JP), S. Sugai et al.: "Studies on spasmolytics. I. Synthesis and spasmolytic activities of 4-acyloxy-1(1,3-dioxolan-4-ylmethyl)piperidines" pages 967-976, see the whole article, chart 1 (cited in the application) *
Journal of Medicinal Chemistry, vol. 8, no. 5, September 1965, Washington (US), C.R. Ganellin et al.: "Compounds affecting the central nervous system. I. 4-piperidones and related compounds", pages 619-625, see the whole article, table I *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006635A1 (fr) * 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Derive de carbamate et medicament le contenant
EP0801067A1 (fr) * 1994-12-28 1997-10-15 Yamanouchi Pharmaceutical Co. Ltd. Nouveaux derives de quinuclidine et composition pharmaceutique les contenant
EP0801067A4 (fr) * 1994-12-28 1998-03-11 Yamanouchi Pharma Co Ltd Nouveaux derives de quinuclidine et composition pharmaceutique les contenant
US6017927A (en) * 1994-12-28 2000-01-25 Yamanouchi Pharmaceutical Co., Ltd. Quinuclidine derivatives and medicinal composition thereof
US6174896B1 (en) 1994-12-28 2001-01-16 Yamanouchi Pharmaceutical Co., Ltd. Quinuclidine derivatives and medicinal composition thereof
US6174900B1 (en) * 1995-06-26 2001-01-16 Ss Pharmaceutical Co., Ltd. Substituted piperidine derivative for treating urinary disturbance
WO2005000815A2 (fr) * 2003-06-24 2005-01-06 Novartis Ag Composes organiques
WO2005000815A3 (fr) * 2003-06-24 2005-04-14 Novartis Ag Composes organiques
AU2004251867B2 (en) * 2003-06-24 2008-08-07 Novartis Ag Piperidinium and pyrrolidinium derivatives as ligands for the muscarinic M3 receptor
US7947730B2 (en) 2003-06-24 2011-05-24 Novartis Ag Piperidinium and pyrrolidinium derivatives as ligands for the muscarinic M3 receptor
US8153669B2 (en) 2004-12-24 2012-04-10 Novartis Ag Quaternary ammonium salts as M3 antagonists
US20190023656A1 (en) * 2014-12-19 2019-01-24 The Broad Institute, Inc. Dopamine d2 receptor ligands
US10752588B2 (en) * 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
US11498896B2 (en) 2014-12-19 2022-11-15 The Broad Institute, Inc. Dopamine D2 receptor ligands

Also Published As

Publication number Publication date
CA2072598A1 (fr) 1992-04-24
GB2249093A (en) 1992-04-29
AU8714991A (en) 1992-05-20
ZA918381B (en) 1993-04-21
FI922903L (fi) 1992-06-22
GB9023023D0 (en) 1990-12-05
JPH05504578A (ja) 1993-07-15
GB9122083D0 (en) 1991-11-27
EP0506903A1 (fr) 1992-10-07
PT99299A (pt) 1992-08-31
FI922903A0 (fi) 1992-06-22

Similar Documents

Publication Publication Date Title
DE60129210T2 (de) Zyklische amid-derivate
PL192397B1 (pl) Pochodna 1-(1,2-dipodstawionej piperydynylo)-4-piperydyny, jej zastosowanie, sposób wytwarzania i kompozycja farmaceutyczna
WO1995006635A1 (fr) Derive de carbamate et medicament le contenant
AU673754B2 (en) Tetrazole derivatives having antihistaminic and antiallergic activity
IE73873B1 (en) Heterocyclic compounds and their preparation and use
US10106522B2 (en) Benzimidazole derivatives as antihistamine agents
DE69012650T2 (de) Piperidinderivat, Verfahren zur Herstellung davon und dieses enthaltende pharmazeutische Zusammensetzung.
AU740662B2 (en) 1,4-disubstituted piperazines
US5190953A (en) Heterocyclic carboxylic acid amides and esters of azabicyclic compounds as gastric prokinetic, antiemetic, anxiolytic and antiarrhythmic agents
WO1992006958A1 (fr) Derives de 4-acetoxy-piperidine, procede servant a leur preparation, et leur utilisation comme antagonistes de recepteur m3 de muscarine
WO2001044193A1 (fr) Analogues de piperidine 1,3,4-substituee et leurs utilisations dans le traitement de la toxicomanie
DE68917185T2 (de) 4-Aryl-4-piperidine (oder -pyrrolidin- oder -hexahydroazepin-) carbinole und heterocyclische Analoga davon.
AU688186B2 (en) (Thiophen-2-YL)-piperidin or tetrahydropyridin carboxamides
Martin-Smith et al. Relationships between the chemical structure and pharmacological activity in a series of synthetic quinuclidine derivatives
US5753678A (en) Heterocyclic compounds
WO1993007122A1 (fr) Piperidines de 4-diphenylacetoxy a substitution n presentant une activite antimuscarinique
EP0364091B1 (fr) 4-(4-(3-Benzisothiazolyl)-1-pipérazinyl)butylimides pontés et bicycliques à activité antipsychotique
US4716166A (en) Histamine H1 antagonists
JPH0741481A (ja) 両性型三環系化合物
EP0451772A1 (fr) Composés de la pipéridine, méthode pour leur préparation et compositions pharmaceutiques les contenant
US20040038966A1 (en) Cyclic amine derivatives and use thereof
EP0785195A1 (fr) Dérivés de piperidine ou tétrahydropyridine avec affinité pour le récepteur de sérotonine 5-HTIA
EP0707579B1 (fr) Methanoanthracenes substitues de piperidinyle en tant qu'antagonistes de d1/d2 et en tant qu'antagonistes de serotonine de 5ht2
WO1996031471A1 (fr) Nouveau procede
EP1151993A1 (fr) Derives d'amine cyclique et leurs utilisations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA FI JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1991917741

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2072598

Country of ref document: CA

Ref document number: 922903

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1991917741

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991917741

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载